Figure 1.
Measurement of mice body weight. During the treatment, no significant difference in bodyweight was observed among control, Alzheimer’s disease-like (AD-like)miceand sulforaphane-treated Alzheimer’s disease-like (AD+SFN-like) mice (n = 18; mean ± S.E.M.; One-way analysis of variance followed by post hoc least significant difference multiple comparison tests).